Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872684 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
A NA study of Aneurysm and Aneurysm, Intracranial, sponsored by Stryker Neurovascular.
- Recruiting
- Registry status
- NA
- Development phase
- 183
- Enrollment target
- 3
- Study locations
NCT06872684: Recruiting NA study of Aneurysm and Aneurysm, Intracranial, sponsored by Stryker Neurovascular.
NCT06872684 is a NA study of Aneurysm and Aneurysm, Intracranial that is actively recruiting participants, run by Stryker Neurovascular. The registered enrollment target is 183 participants, below the 17,066-participant average among 6 other Aneurysm trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06872684, a NA study of Aneurysm and Aneurysm, Intracranial, is actively recruiting participants, sponsored by Stryker Neurovascular.
- RECRUITING
- Registry status
- NA
- Development phase
- 183 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.
Primary Outcome
Neurological death defined as stroke-related death and related to the vascular territory associated with target aneurysm treatment. Major ipsilateral stroke defined as a stroke with an increase in National Institutes of Health Stroke Scale (NIHSS) score ≥ 4 points persisting ≥ 24 hours and related to the vascular territory associated with target aneurysm treatment.
Conditions Studied
Interventions
- DEVICE Surpass Elite with Guardian Flow Diverter System
Study Locations (3)
Arizona
- Carondelet St. Joseph's Hospital - Tucson
California
- University of California Davis Health - Davis
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2031-01-31 |
| Phase | NA |
What NCT06872684 shows while recruiting
NCT06872684 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 17,066-participant average among 6 other Aneurysm trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which Surpass Elite with Guardian Flow Diverter System is the first listed.
NCT06872684 reports a single indexed study location in Arizona, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06872684 about?
NCT06872684 is a clinical study titled "Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)". The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck sac...
What is the current status of trial NCT06872684?
This trial is currently recruiting. It is a NA study. The enrollment target is 183 participants. The study started on 2025-06-20. Estimated completion is 2031-01-31.
What conditions does trial NCT06872684 study?
This clinical trial studies the following conditions: Aneurysm, Aneurysm, Intracranial.
What interventions are being tested in trial NCT06872684?
The interventions under investigation include: Surpass Elite with Guardian Flow Diverter System (DEVICE).
Who is sponsoring clinical trial NCT06872684?
This trial is sponsored by Stryker Neurovascular, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872684 being conducted?
This trial has 3 study locations across Arizona, California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aneurysm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)
RECRUITING · NA
-
An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
RECRUITING
-
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
RECRUITING · Phase 1
-
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
RECRUITING
-
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
COMPLETED · Phase 2
-
Doppler Flow Wires in Cerebral Angiography
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06922591 · 183 participants · Phase 1
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI